Kymera Therapeutics

Selective IRAK4 Degradation, Not Kinase Inhibition, Blocks TLR-activated NF-kB and p38 Signaling Leading to broad Cytokine Inhibition

The American Association of Immunologists (AAI) Immunology2022(TM), May 6-10, 2022